Cyclic vs Daily Progesterone With HRT: Doses, Bleeding and Switching

Cyclic and daily oral micronized progesterone organize menopausal hormone therapy around different calendars. Cyclic treatment often includes a withdrawal bleed after the progesterone course. Daily treatment has no planned withdrawal interval, although bleeding can still occur. The distinction matters when deciding what bleeding to expect and when reviewing a proposed change. [2]

For someone with a uterus using systemic estrogen, progesterone or another appropriate progestogen provides endometrial protection. Estrogen alone is generally used after total hysterectomy, with exceptions individualized. That starting point comes before choosing a calendar. [8]

Compare the calendar, formulation and evidence

“Progesterone 100 mg” does not describe a complete regimen. The product, estrogen exposure and number of treatment days also matter. The table separates specific product instructions from specialist-guidance examples.

Keep the estrogen prescription next to the progesterone instructions when comparing options. The capsule strength alone cannot tell you which days to take it.

Why monthly milligrams cannot settle the choice

Adding the progesterone taken over a month is easy. Using that sum to claim equivalent protection is not supported by these sources. For example, 200 mg for 12 days totals 2,400 mg, whereas 100 mg over 28 days totals 2,800 mg. That is arithmetic, not evidence of equal endometrial protection.

The PEPI trial illustrates why the actual studied schedule matters. In 596 women followed for three years, investigators compared placebo, conjugated equine estrogen alone and three estrogen–progestogen regimens. The micronized progesterone arm used 200 mg during the first 12 days of each cycle alongside conjugated equine estrogen 0.625 mg. The combined regimens protected against endometrial hyperplasia. The study tested the 12-day progesterone schedule; it does not establish that a shorter course would work equally well. [4]

That evidence supports a defined combination and schedule. It cannot answer every question about another estrogen dose, a different capsule formulation or a shortened progesterone course. A comparison should retain those boundaries rather than translating a trial into a monthly-milligram target.

Bleeding expectations and switching calendars

BMS guidance uses at least 12 days of micronized progesterone monthly for sequential treatment; the minimum 10-day schedules for norethisterone or medroxyprogesterone acetate should not be substituted. Higher estrogen doses need proportionate progestogen. Stage, history, bleeding and tolerance influence the choice; reaching 12 months on treatment is not an automatic instruction to switch. [2]

Before changing, confirm the exact prescribed calendar: the final day of the current course, the first day of the replacement schedule and whether the estrogen instructions also change. “Take it continuously” should leave no uncertainty about which product to take or on which dates. This is particularly important when moving between separate prescriptions and a combined capsule.

Keep a dated bleeding record, including whether an episode followed the end of a cyclic course or occurred unexpectedly. Bring heavy, persistent or new bleeding to the prescriber rather than changing the hormone schedule to suppress it. [2]

Keep product instructions attached to the product

Prometrium contains peanut oil, and dizziness or drowsiness matters when reviewing tolerability. Its separate 400 mg amenorrhea schedule is not a substitute for the endometrial-protection schedule. [1] Bijuva has its own evening-with-food instruction. [3] These details are reasons to check the actual package and prescription rather than work from the word “progesterone” alone.

The estrogen prescription deserves the same precision. A patch’s daily delivery rate and its replacement frequency are different instructions. For a focused explanation, see estradiol patch dosing. Vivelle-Dot, for example, has indication-specific starting doses and twice-weekly replacement. [9] Neither a patch number nor an oral estrogen dose independently identifies the appropriate progesterone calendar.

An optional prescription-calendar record

A brief record can make a review more concrete. Copy the exact product name, strength and prescribed days; record the days actually taken, estrogen schedule, missed doses and bleeding dates. Keep the prescription instructions separate from what happened in practice, so a missed capsule is not mistaken for the intended schedule.

This record is a memory aid, not a dosing algorithm. It does not determine whether bleeding is safe or authorize extra capsules. Bring uncertainties about the calendar to the prescriber before making a change. HRT is not contraception.

Reviewing the whole regimen

NICE recommends review at three months and annually thereafter, sooner when needed. [8] Review can address whether the current product and calendar still fit the person’s symptoms, bleeding experience and tolerance. Menopausal hormone therapy risks vary with type, dose, route, duration and timing, so reevaluation should consider the whole regimen rather than progesterone milligrams alone. [5]